SCHEMBL21592282

SCHEMBL21592282

COc1ccc2ccc3c(=O)c(CN(CCCn4cnc5ccccc54)Cc4ccncc4)coc3c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 2/20 0.40
▸ CYP11B2 P19099 2/20 0.40
▸ KCNA5 P22460 6/20 0.37
▸ POLB P06746 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAOB P27338 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CDYL2 Q8N8U2 1/20 0.34
▸ CDYL Q9Y232 1/20 0.34
▸ CDY1; CDY1B Q9Y6F8 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KCNJ5 P48544 2/20 0.34
▸ KCNJ3 P48549 2/20 0.34
▸ BCHE P06276 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21592291 0.89 KMT2A (0.35) CYP11B1CYP11B2KCNA5POLBSMN1; SMN2
SCHEMBL21591545 0.85 SMN1; SMN2 (0.33) KCNA5POLBPKMSMN1; SMN2MEN1
SCHEMBL21592298 0.85 KCNA5 (0.36) CYP11B1CYP11B2KCNA5MAOBKCNJ5
SCHEMBL21592285 0.81 KCNA5 (0.36) CYP11B1CYP11B2KCNA5POLBMEN1
SCHEMBL21591431 0.80 CYP11B1 (0.48) CYP11B1CYP11B2SMN1; SMN2MAOBHTT
SCHEMBL21592250 0.80 KCNA5 (0.44) CYP11B1CYP11B2KCNA5POLBMAPT
SCHEMBL21591551 0.79 MEN1 (0.33) POLBSMN1; SMN2MEN1HTTKMT2A
SCHEMBL21592278 0.76 POLB (0.38) CYP11B1CYP11B2KCNA5POLBMEN1
SCHEMBL21592297 0.75 FNTA (0.33) CYP11B1CYP11B2POLBPKMMEN1
SCHEMBL31361796 0.75 FNTA (0.33) CYP11B1CYP11B2POLBPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US claimed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US claimed
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885KCNA5 2592/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS CYP11B1 43/4885CYP11B2 50/4885KCNA5 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback